Close Menu

NEW YORK – Natera said this week that it has launched a multi-site prospective study to externally validate a new algorithm for its Prospera donor-derived cell-free DNA transplant rejection test. The PEDAL (Prospera Test Enhancement by Detecting Background Cell-Free DNA Levels) study will enroll 500 kidney transplant patients at 20 major centers in the US and will start recruitment soon.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.